From a small beginning that was initiated way back with the post acquisition of majority shareholding of Dabur Pharma by Fresenius Kabi, the Company has indeed come a long way and established itself as a leading player in the field of oncology generics. Fresenius Kabi Oncology Limited has innovated and developed many life-saving products for cancer patients. We are a company with rich and diverse corporate heritage and with this prophecy we have strived and continued to provide unmatched facilities for R&D and manufacturing in the diverse field of Oncology Generics and its intricate field of research.
Year | Successful Development |
2003
|
Dabur India Ltd. spins off the pharmaceutical business into Dabur Pharma Limited.
|
---|---|
2008
|
The Burman family, promoters of the Dabur Pharma Group divested its entire stake in Dabur Pharma Ltd. to Fresenius Kabi, a business segment of Fresenius SE & Co. KGaA, a German Multinational with business interests across the globe.
|
2009
|
Post integration with Fresenius Kabi, the name of the Company was changed in order to synchronize the same with Fresenius Kabi.
|
2010
|
Opening of newly developed premier Innovation & Development Center and Corporate Office at Gurgaon.
|